Brytton Long, DO
Family Medicine · Rock Springs, WYNPI 1063709905
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$483
- AbbVie$326
- Amgen$288
- Merck$227
- Lilly USA, LLC$201
- Pfizer$176
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,161100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $483 |
| AbbVie | 14 | $326 |
| Amgen | 17 | $288 |
| Merck | 16 | $227 |
| Lilly USA, LLC | 15 | $201 |
| Pfizer | 11 | $176 |
| GSK | 9 | $156 |
| Novo Nordisk | 11 | $155 |
| Otsuka America Pharmaceutical, Inc. | 8 | $140 |
| Corium, LLC | 4 | $88 |
| Dexcom, Inc. | 3 | $73 |
| Supernus Pharmaceuticals, Inc. | 5 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $69 |
| Amarin Pharma, Inc. | 5 | $66 |
| Lundbeck LLC | 3 | $62 |
| Johnson & Johnson | 4 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Novartis | 3 | $56 |
| Viatris Specialty LLC | 2 | $53 |
| Eisai Inc. | 4 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $48 |
| Ironshore Pharmaceuticals Inc. | 2 | $48 |
| Mylan Specialty L.p. | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Exact Sciences | 1 | $15 |
| Biogen | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$3,161 in reported general payments places this provider in the 90th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $56,178 |
| EliquisApixaban | 59 | $51,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $46,406 |
| JanuviaSitagliptin Phosphate | 25 | $34,977 |
| TrulicityDulaglutide | 25 | $33,411 |
| MounjaroTirzepatide | 26 | $28,372 |
| FarxigaDapagliflozin Propanediol | 25 | $25,104 |
| XareltoRivaroxaban | 13 | $21,042 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $19,631 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $17,806 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $12,946 |
| TradjentaLinagliptin | 16 | $10,431 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $9,748 |
| BelsomraSuvorexant | 18 | $7,625 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $201 | $61,78351 claims |
| Novo NordiskOzempic | $155 | $56,17841 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $227 | $55,54758 claims |
| PfizerEliquis | $176 | $51,62259 claims |
| GSKTrelegy Ellipta | $156 | $46,40657 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $483 | $42,91146 claims |
| Johnson & JohnsonXarelto | $62 | $21,04213 claims |
| Boehringer IngelheimTradjenta | $34 | $10,43116 claims |
| Corium, LLCAzstarys | $88 | $4,70811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Rock Springs
- Jacob JohnsonRock Springs$5K
- Lawrence LauridsenRock Springs$4K
- Melinda PoyerRock Springs$2K
- David DansieRock Springs$1K
- Michael BowersRock Springs$1K
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Jonathon MedinaCheyenne$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.